Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Fig. 2

Median percentage changes from baseline in biomarkers through week 24. Median percentage changes from baseline in biomarkers of a, b the acute-phase response (CRP and SAA), cf bone remodelling (P1NP, OC, total RANKL and OPG), g synovial inflammation (MMP-3) and h atherothrombosis (Lp [a]). *Adjusted p < 0.05; **adjusted p < 0.01 vs. adalimumab; ***adjusted p < 0.0001 vs. adalimumab (Benjamini–Hochberg procedure). CRP, C-reactive protein; Lp(a), lipoprotein (a); MMP-3, matrix metalloproteinase-3; OC, osteocalcin; OPG, osteoprotegerin; P1NP, procollagen type 1 N-terminal propeptide; Q, quartile; q2w, every 2 weeks; RANKL, receptor activator of nuclear factor-κB ligand; SAA, serum amyloid A

Back to article page